Invesco
SYRE icon

Invesco’s Spyre Therapeutics SYRE Stock Holding History

Invesco’s Portfolio SYRE Stock Details SYRE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$10.7M Sell
120,541
-11,849
-9% -$865K ﹤0.01% 1856
2026
Q1 		$6.68M Sell
132,390
-18,544
-12% -$699K ﹤0.01% 2052
2025
Q4 		$4.94M Buy
150,934
+100,232
+198% +$2.62M ﹤0.01% 2245
2025
Q3 		$850K Buy
50,702
+16,022
+46% +$261K ﹤0.01% 3009
2025
Q2 		$519K Buy
34,680
+9,473
+38% +$140K ﹤0.01% 3141
2025
Q1 		$407K Buy
25,207
+5,544
+28% +$115K ﹤0.01% 3238
2024
Q4 		$458K Sell
19,663
-118,195
-86% -$3.47M ﹤0.01% 3274
2024
Q3 		$4.05M Buy
137,858
+121,494
+742% +$3.38M ﹤0.01% 2343
2024
Q2 		$385K Sell
16,364
-136,214
-89% -$4.59M ﹤0.01% 3391
2024
Q1 		$5.79M Buy
+152,578
New +$4.42M ﹤0.01% 2136
2022
Q2 		– Sell
-494
Closed -$29K – 4141
2022
Q1 		$29K Buy
494
+6
+1% +$504 ﹤0.01% 3967
2021
Q4 		$58K Sell
488
-101
-17% -$15.9K ﹤0.01% 3966
2021
Q3 		$117K Buy
589
+67
+13% +$11.7K ﹤0.01% 3910
2021
Q2 		$90K Buy
+522
New +$94.9K ﹤0.01% 3908
2020
Q3 		– Sell
-2,507
Closed -$580K – 3686
2020
Q2 		$580K Buy
+2,507
New +$477K ﹤0.01% 3062
2018
Q4 		– Sell
-1,053
Closed -$252K – 3871
2018
Q3 		$252K Sell
1,053
-390
-27% -$91.1K ﹤0.01% 3637
2018
Q2 		$382K Buy
+1,443
New +$355K ﹤0.01% 3516

Other funds holding SYRE

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
PA
Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return
RI
RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return
PBA
Paradigm Biocapital Advisors New York $5.34B AUM 380.18% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
VA
VR Adviser New York $3.3B AUM 525.74% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
DCM
Driehaus Capital Management Chicago, Illinois $17.3B AUM 211.34% 1-Year Est. Return

Invesco's SYRE Position: Q2 2026 in Review

Invesco reduced its Spyre Therapeutics (SYRE) stake by 9% in Q2 2026, selling an estimated $865K and leaving 120,541 shares worth $10.7M. The position accounts for ﹤0.01% of the portfolio, ranked #1856.

Invesco first reported a position in SYRE in Q2 2018 and has held it in 17 quarters since. 265 funds tracked by Wall St. Rank hold SYRE as of Q2 2026.

  • Invesco held 120,541 shares of Spyre Therapeutics worth $10.7M as of Q2 2026.
  • Invesco sold 11,849 Spyre Therapeutics shares in Q2 2026, an estimated $865K.
  • Spyre Therapeutics made up ﹤0.01% of Invesco's portfolio in Q2 2026, its #1856 holding.
  • Invesco first reported a position in Spyre Therapeutics in Q2 2018 and has held it in 17 quarters since.
  • 265 funds tracked by Wall St. Rank held Spyre Therapeutics as of Q2 2026.

Based on Invesco's 13F filing for Q2 2026, filed 14 Aug 2026.